

GAA Gene Analysis in Pompe Disease / Glycogen Storage Disease II

CLINICAL FEATURES

Pompe Disease / Glycogen Storage Disease II (GSDII) is a rare lysosomal storage disease. Patients have been classified as infantile, juvenile or adult onset types. More recently, it has been recognized that there is a continuum of phenotypes between the classical infantile onset and the adult form. Infantile GSDII presents during the first weeks or months of life with poor feeding, failure to thrive, macroglossia, severe hypotonia, cardiomegaly, mild hepatomegaly, and respiratory insufficiency. There is often a rapid progression to cardiac failure and death typically occurs within the first year. Later onset forms are characterized by skeletal muscle weakness, respiratory insufficiency and hepatomegaly. Cardiac involvement is usually absent or mild. The adult onset form presents in the third to sixth decade and is similar to the juvenile form but with a slower progression of skeletal muscle weakness.¹

GENETICS

GSDII is caused by pathogenic variants in the GAA gene that encodes the enzyme alpha-1,4-glucosidase, which degrades alpha-1,4 and alpha-1,6 linkages in glycogen, maltose and isomaltose. Enzyme deficiency leads to lysosomal accumulation of glycogen which may eventually lead to cardiac failure and/or skeletal muscle dysfunction. The severity of the disease is related to the degree of enzyme deficiency. The GAA gene is located on chromosome 17q25.2-q25.3 and contains 20 exons, the first of which is not translated. The incidence of GSDII has been estimated at 1 in 40,000 in the western world.^{1,2}

INHERITANCE PATTERN

Autosomal Recessive

TEST METHODS

Variant analysis of the GAA gene is performed on genomic DNA from the submitted specimen using bi-directional sequence analysis of coding exons (2-20), and corresponding intron/exon boundaries. In addition, targeted array CGH analysis with exon-level resolution (ExonArrayDx) is performed concurrently to evaluate for a deletion or duplication of one or more exons of this gene. A variant is confirmed by repeat analysis using sequencing, restriction fragment analysis, quantitative PCR or oligo-array comparative genome hybridization (ExonArrayDx), as appropriate.

The methods used by GeneDx are expected to be greater than 99% sensitive at detecting variants identifiable by sequencing.

VARIANT SPECTRUM

GAA variants are spread throughout the gene and include missense, nonsense, splicing, and both small and large deletions and insertions. A large deletion of exon 18 has been identified in 5-8% of GAA alleles in patients with both infantile and adult-onset GSDII from diverse ethnic backgrounds.^{4,5,7,8} This variant occurs at even higher frequency in the Dutch population (13% of patients in one study in which 58% of patients were Dutch), and has been proposed to be a founder mutation in this population.^{6,9} The most common variant among adults is c.-32-13 T>G occurring in approximately 77% of patients from diverse ethnic backgrounds with adult-onset GSDII. The majority of GSDII patients are compound heterozygotes despite the high frequency of the c.-32-13 T>G variant. A genotype-phenotype correlation has been identified.^{1,2,3}

REFERENCES:

1. Raben et al. (2002) Curr. Mol. Med. 2 (2):145-66 (PMID: 11949932)
2. Kroos et al. (2007) Neurology 68 (2):110-5 (PMID: 17210890)
3. Hermans et al. (2004) Hum. Mutat. 23 (1):47-56 (PMID: 14695532)
4. McCready et al. (2007) Molecular Genetics And Metabolism 92 (4):325-35 (PMID: 17723315)
5. Oba-Shinjo et al. (2009) Journal Of Neurology 256 (11):1881-90 (PMID: 19588081)
6. Pittis et al. (2008) Human Mutation 29 (6):E27-36 (PMID: 18429042)
7. Joshi et al. (2008) Journal Of Inherited Metabolic Disease 31 Suppl 2 :S261-5 (PMID: 18607768)
8. Van der Kraan et al. (1994) Biochemical And Biophysical Research Communications 203 (3):1535-41 (PMID: 7945303)
9. Kroos et al. (1995) J. Med. Genet. 32 (10):836-7 (PMID: 8558570)